Peringatan Keamanan

Oral, mouse: LD50 = 423 mg/kg; Oral, rat: LD50 = 305 mg/kg.

Vinblastine

DB00570

small molecule approved

Deskripsi

Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

Struktur Molekul 2D

Berat 810.9741
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Triphasic: 35 min, 53 min, and 19 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Hepatic. Metabolism of vinblastine has been shown to be mediated by hepatic cytochrome P450 3A isoenzymes.

Rute Eliminasi

The major route of excretion may be through the biliary system.

Interaksi Makanan

2 Data
  • 1. Avoid grapefruit products. Grapefruit inhibits CYP3A metabolism, which may increase the serum concentration of vinblastine.
  • 2. Exercise caution with St. John's Wort. This herb induces CYP3A metabolism, which may reduce serum levels of vinblastine.

Interaksi Obat

1319 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Vinblastine.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vinblastine.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Vinblastine.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Vinblastine.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Vinblastine.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Vinblastine.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Vinblastine.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vinblastine.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vinblastine.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vinblastine.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vinblastine.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Vinblastine.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Vinblastine.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Vinblastine.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vinblastine.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Vinblastine.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vinblastine.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Vinblastine.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Vinblastine.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vinblastine.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vinblastine.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Vinblastine.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vinblastine.
Cladribine Vinblastine may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Vinblastine.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Vinblastine.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Vinblastine.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Vinblastine.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Vinblastine.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Vinblastine.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Vinblastine.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Vinblastine.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Vinblastine.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Vinblastine.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Vinblastine.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Vinblastine.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Vinblastine.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Vinblastine.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Vinblastine.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Vinblastine.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Vinblastine.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Vinblastine.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Vinblastine.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Vinblastine.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Vinblastine.
Linezolid The risk or severity of adverse effects can be increased when Vinblastine is combined with Linezolid.
Clofarabine The risk or severity of adverse effects can be increased when Vinblastine is combined with Clofarabine.
Prednisone The risk or severity of adverse effects can be increased when Vinblastine is combined with Prednisone.
Pemetrexed The risk or severity of adverse effects can be increased when Vinblastine is combined with Pemetrexed.
Fludrocortisone The risk or severity of adverse effects can be increased when Vinblastine is combined with Fludrocortisone.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Vinblastine is combined with Mycophenolate mofetil.
Tretinoin The risk or severity of cardiotoxicity can be increased when Vinblastine is combined with Tretinoin.
Sulfasalazine The risk or severity of adverse effects can be increased when Vinblastine is combined with Sulfasalazine.
Dacarbazine The risk or severity of adverse effects can be increased when Vinblastine is combined with Dacarbazine.
Temozolomide The risk or severity of adverse effects can be increased when Vinblastine is combined with Temozolomide.
Penicillamine The risk or severity of adverse effects can be increased when Vinblastine is combined with Penicillamine.
Mechlorethamine The risk or severity of adverse effects can be increased when Vinblastine is combined with Mechlorethamine.
Azacitidine The risk or severity of adverse effects can be increased when Vinblastine is combined with Azacitidine.
Carboplatin The risk or severity of adverse effects can be increased when Vinblastine is combined with Carboplatin.
Dactinomycin The risk or severity of adverse effects can be increased when Vinblastine is combined with Dactinomycin.
Azathioprine The risk or severity of adverse effects can be increased when Vinblastine is combined with Azathioprine.
Hydroxyurea The risk or severity of adverse effects can be increased when Vinblastine is combined with Hydroxyurea.
Mycophenolic acid The risk or severity of adverse effects can be increased when Vinblastine is combined with Mycophenolic acid.
Mercaptopurine The risk or severity of adverse effects can be increased when Vinblastine is combined with Mercaptopurine.
Thalidomide The metabolism of Vinblastine can be increased when combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Vinblastine is combined with Melphalan.
Fludarabine The risk or severity of adverse effects can be increased when Vinblastine is combined with Fludarabine.
Flucytosine The risk or severity of adverse effects can be increased when Vinblastine is combined with Flucytosine.
Capecitabine The risk or severity of adverse effects can be increased when Vinblastine is combined with Capecitabine.
Procarbazine The risk or severity of adverse effects can be increased when Vinblastine is combined with Procarbazine.
Idarubicin The risk or severity of adverse effects can be increased when Vinblastine is combined with Idarubicin.
Estramustine The risk or severity of adverse effects can be increased when Vinblastine is combined with Estramustine.
Lomustine The risk or severity of adverse effects can be increased when Vinblastine is combined with Lomustine.
Eculizumab The risk or severity of adverse effects can be increased when Vinblastine is combined with Eculizumab.
Decitabine The risk or severity of adverse effects can be increased when Vinblastine is combined with Decitabine.
Nelarabine The risk or severity of adverse effects can be increased when Vinblastine is combined with Nelarabine.
Ciclesonide The risk or severity of adverse effects can be increased when Vinblastine is combined with Ciclesonide.
Stepronin The risk or severity of adverse effects can be increased when Vinblastine is combined with Stepronin.
Hydroxychloroquine The risk or severity of adverse effects can be increased when Vinblastine is combined with Hydroxychloroquine.
Castanospermine The risk or severity of adverse effects can be increased when Vinblastine is combined with Castanospermine.
Vorinostat The risk or severity of adverse effects can be increased when Vinblastine is combined with Vorinostat.
2-Methoxyethanol The risk or severity of adverse effects can be increased when Vinblastine is combined with 2-Methoxyethanol.
Brequinar The risk or severity of adverse effects can be increased when Vinblastine is combined with Brequinar.
Aldosterone The risk or severity of adverse effects can be increased when Vinblastine is combined with Aldosterone.
Pirfenidone The risk or severity of adverse effects can be increased when Vinblastine is combined with Pirfenidone.
Interferon alfa The risk or severity of adverse effects can be increased when Vinblastine is combined with Interferon alfa.
Glatiramer The risk or severity of adverse effects can be increased when Vinblastine is combined with Glatiramer.
Briakinumab The risk or severity of adverse effects can be increased when Vinblastine is combined with Briakinumab.
Human interferon omega-1 The risk or severity of adverse effects can be increased when Vinblastine is combined with Human interferon omega-1.
Mepolizumab The risk or severity of adverse effects can be increased when Vinblastine is combined with Mepolizumab.
Abetimus The risk or severity of adverse effects can be increased when Vinblastine is combined with Abetimus.
Belatacept The risk or severity of adverse effects can be increased when Vinblastine is combined with Belatacept.
Bendamustine The risk or severity of adverse effects can be increased when Vinblastine is combined with Bendamustine.
Pralatrexate The risk or severity of adverse effects can be increased when Vinblastine is combined with Pralatrexate.
Wortmannin The risk or severity of adverse effects can be increased when Vinblastine is combined with Wortmannin.
Eribulin The risk or severity of adverse effects can be increased when Vinblastine is combined with Eribulin.
Belimumab The risk or severity of adverse effects can be increased when Vinblastine is combined with Belimumab.
Teriflunomide The risk or severity of adverse effects can be increased when Vinblastine is combined with Teriflunomide.
Dimethyl fumarate The risk or severity of adverse effects can be increased when Vinblastine is combined with Dimethyl fumarate.
Obinutuzumab The risk or severity of adverse effects can be increased when Vinblastine is combined with Obinutuzumab.

Target Protein

Tubulin beta-2A chain TUBB2A
Tubulin alpha-1A chain TUBA1A
Tubulin beta chain TUBB
Tubulin delta chain TUBD1
Tubulin gamma-1 chain TUBG1
Tubulin epsilon chain TUBE1
Transcription factor Jun JUN

Referensi & Sumber

Synthesis reference: Pierre Potier, Pierre Mangeney, Nicole Langlois, Yves Langlois, "Process for the synthesis of vinblastine and leurosidine." U.S. Patent US4305875, issued October, 1977.
Artikel (PubMed)
  • PMID: 942954
    Starling D: Two ultrastructurally distinct tubulin paracrystals induced in sea-urchin eggs by vinblastine sulphate. J Cell Sci. 1976 Jan;20(1):79-89.

Contoh Produk & Brand

Produk: 7 • International brands: 12
Produk
  • Velbe 1mg/ml
    Powder, for solution • 10 mg / 10 mL • Intravenous • Canada • Approved
  • Vinblastine Sulfate
    Injection, powder, lyophilized, for solution • 10 mg/10mL • Intravenous • US • Generic • Approved
  • Vinblastine Sulfate
    Injection • 1 mg/1mL • Intravenous • US • Generic • Approved
  • Vinblastine Sulfate Inj 1mg/ml
    Liquid • 1 mg / mL • Intravenous • Canada • Approved
  • Vinblastine Sulfate Injection
    Solution • 1 mg / mL • Intravenous • Canada • Approved
  • Vinblastine Sulfate Injection
    Solution • 1 mg / mL • Intravenous • Canada • Approved
  • Vinblastine Sulphate Injection
    Solution • 1 mg / mL • Intravenous • Canada • Approved
International Brands
  • Blastivin — Pharmachemie
  • Cytoblastin — Cipla
  • Lemblastine
  • Oncostin — Cipla
  • Velban — ABL Antibióticos do Brasil
  • Velbastin — Korea United Pharm
  • Velbe — STADA
  • Vinblasin — Teva
  • Vinblastin — Gedeon Richter
  • Vinko — Koçak

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul